Brilacidin is closest to approval and it makes sense to focus on it. Plus, fleshing out other applications makes that platform more valuable.
I'm anxious to see full Kevetrin results and don't view Prurisol as an afterthought. It's more of a bonus.
Have a good day all... I'm off for a bike ride. It's a gorgeous day out. ;)
In Reply to 'voisybay123' Thanks--I've read your interviews with Leo and invested slowly since that time (it has been a long wait to get to this point)-the earlier mouse studies did use human xenografts implanted in mice without immune systems--the results (showing no real visible psoriasis lesions) were quite remarkable (as was the results compaing prurisol vs methotrexate)---since this was in fact human tissue with a mouse blood supply I do believe we will see a good result--have xenograft drug trials failed miserably before??---this clinical design seems to be as close to using a human subject (like the trial to be reported this week) as you can get. The only thing I do worry about is that the company seems to be treating Prurisol as an "afterthought"--almost all press releases have focused on Brucilidin and Kevetrin--Leo in fact seems to be fixated on Kevitrin
News 
Market Data 
Discover 
